步步受困诺和诺德真高兴不起来有点数·数字经济工作室原创作 者 | 有 叔微信ID | yds_sh丹麦制药巨头诺和诺德最近发布了2025上半年财报,“减肥神药”司美格鲁肽三款剂型实现1127.56亿丹麦克朗(约167亿美元)的销售额,合计贡献近73%的营收,这被视作司美格鲁肽正式接过K药全球“药王”权杖的关键一刻。然而市场对此反应极为冷淡,截至8月8日,公司股价单日暴跌21.8%,市值...
Source Link步步受困诺和诺德真高兴不起来有点数·数字经济工作室原创作 者 | 有 叔微信ID | yds_sh丹麦制药巨头诺和诺德最近发布了2025上半年财报,“减肥神药”司美格鲁肽三款剂型实现1127.56亿丹麦克朗(约167亿美元)的销售额,合计贡献近73%的营收,这被视作司美格鲁肽正式接过K药全球“药王”权杖的关键一刻。然而市场对此反应极为冷淡,截至8月8日,公司股价单日暴跌21.8%,市值...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.